- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02196285
Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella (MR)
June 21, 2016 updated by: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
A Phase I, Open, Uncontrolled Study, to Evaluate the Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella in Young Adults
Measles and rubella are highly contagious acute viral diseases.
As per WHO, several evidences demonstrate the benefit for providing the universal access to vaccines containing measles and rubella antigens, mainly due to, respectively, mortality in children and malformations in fetuses.
This is a Phase I, open study, non-controlled, to evaluate the safety, tolerability and imunogenicity of double viral vaccine anti-measles and rubella (MR), which is developed and produced at Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in human beings.
30 eligible volunteers, between 18-49 years old, will be vaccinated and monitored for local and systemic adverse events and titration of antibodies.
The study will last 20 months in total.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This is a Phase I, open study, non-controlled, to evaluate the safety, tolerability and imunogenicity of double viral vaccine anti-measles and rubella (MR), which is developed and produced at Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in human beings.
30 eligible volunteers, between 18-49 years old, will be vaccinated and monitored for local and systemic adverse events and titration of antibodies.
The study will last 20 months in total.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
RJ
-
Rio de Janeiro, RJ, Brazil, 21040900
- Unidade de Ensaios Clínicos para Imunobiológicos
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male
- Age between 18 and 49 years old;
- Willing to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications);
- Willing to strictly follow the study protocol;
- Capacity for understanding and signing in the Informed Consent Form;
- To understand the impossibility of participating in another clinical trial during the time of participation in the study, until 6 months after its conclusion;
- Intellectual level which allows to filling in the diaries for registering of symptoms at home;
- Willing to undergo to serological testing to HIV, HBV and HCV;
- Being in good health, with no significant medical history;
- Physical examination at screening period without clinically significant changes;
- Lab examination at screening period within the normal ranges, determined by the laboratory or abnormal values, grading below 1 or 2, according to medical decision.
Exclusion Criteria:
- Serious adverse reaction to any vaccination, as respiratory difficulty, angioedema and anaphylaxis;
- Acute or chronic disease, as diabetes, heart disease, systemic arterial hypertension;
- Use of anti-allergic with antigen injections in a maximum timeline of 14 days before the vaccination;
- Use of immunoglobulin in the past 12 months before the study vaccination;
- Use of blood products within 12 months before the vaccination;
- Use of any vaccine type within 30 days before the vaccination of the study;
- Chronic use of any medication, except homeopathy, and trivial ones, as nasal physiologic solution and vitamins;
- Previous immunosuppressive or cytotoxic medication, in the last 6 months. Individuals who have made use of this kind of medication in non-immunosuppressant doses, as nasal corticosteroid for allergic rhinitis of topic corticosteroid for non-complicated dermatitis, for more than 14 days, are allowed to be included in the study.
- Use of any kind of medication under investigation within one year before the vaccination.
- Unstable asthma or which may have required urgent care, hospitalization or intubation within the last 2 years, or which requires use of oral or intravenous corticosteroid.
- Coagulopathies diagnosed by a physician or report of capillary fragility (ex: bruises or bleedings without justifiable cause;
- Convulsions, except the ones caused by fever, before 2 years old;
- Psychiatric disease which difficults the adherence to the protocol, such as psychosis, obsessive-compulsive disorders, bipolar disease under treatment, diseases which require treatment with lithium and suicidal ideas in the last 5 years from the inclusion;
- Active malignant (p.e. any kind of cancer) or treated disease, to which the individual may relapse during the study;
- Asplenia (absence of spleen or its removal);
- Positive HIV in the screening examination of history of any immunosuppressant disease;
- Positive serology for C hepatitis in the screening evaluation;
- Positive Antigen HBs in the screening evaluation;
- Alcoholism (CAGE criteria), used for detection of abusive drinkers or alcoholic, validated in the Brazilian population with sensibility of 88% and specificity of 83%, if two or more answers, among four possible, are afirmative(Mansur and Monteiro, 1983), or according to medical decision;
- Abuse of illicit drugs, according to medical decision;
- Acquired or congenital immunodeficiency;
- Allergy to the vaccine compounds, as egg, neomycin and gelatin.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Double viral vaccine (MR)
Measles and rubella vaccine
|
Measles and Rubella vaccine, as single arm
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability analysis of the study vaccine
Time Frame: 9 months
|
To evaluate the occurrence of serious adverse events among the subjects who have received study vaccine.
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Imunogenicity analysis
Time Frame: 9 months
|
To evaluate imune response between post and pre-vaccination antibodies.
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jose CerbinoNeto, PHD, Unidade de Ensaios Clínicos para Imunobiológicos, Fiocruz
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
July 16, 2014
First Submitted That Met QC Criteria
July 21, 2014
First Posted (Estimate)
July 22, 2014
Study Record Updates
Last Update Posted (Estimate)
June 22, 2016
Last Update Submitted That Met QC Criteria
June 21, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASCLIN 002/2014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Measles
-
Bandim Health ProjectHeidelberg University; Centre de Recherche en Sante de Nouna, Burkina Faso; Navrongo... and other collaboratorsUnknownMeasles VaccineBurkina Faso
-
Bandim Health ProjectUnknown
-
Postgraduate Institute of Medical Education and...Unknown
-
Bandim Health ProjectHeidelberg University; Centre de Recherche en Sante de Nouna, Burkina Faso; Navrongo... and other collaboratorsUnknown
-
Serum Institute of India Pvt. Ltd.Centers for Disease Control and Prevention; University of Colorado, BoulderCompletedProphylaxis for the Measles InfectionIndia
-
Bandim Health ProjectEnrolling by invitationMortality | Measles Vaccine | Hospital Admission | Non-specific (Heterologous) Effects of VaccinesGuinea-Bissau
-
GlaxoSmithKlineCompletedMeasles; Mumps; Rubella | Measles-Mumps-Rubella VaccineUnited States, Finland, Taiwan, Estonia, Puerto Rico
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Not yet recruiting
Clinical Trials on Double viral (MR) vaccine
-
Heidelberg UniversityUnknownCholangiographyGermany
-
PT Bio FarmaCompletedSafety Issues | ImmunogenicityIndonesia
-
Jiangsu Province Centers for Disease Control and...RecruitingCOVID-19 | Pulmonary TuberculosisChina
-
Ankara City Hospital BilkentThe Scientific and Technological Research Council of Turkey; MonitorCRORecruiting
-
Centers for Disease Control and PreventionInternational Centre for Diarrhoeal Disease Research, Bangladesh; Ministry...CompletedMeasles | Rubella | Rubella Syndrome, CongenitalBangladesh
-
Hospital Israelita Albert EinsteinMinistry of Health, BrazilCompletedAcute Coronary SyndromeBrazil
-
Washington University School of MedicineCOVID -19 Therapeutics AcceleratorCompletedCOVID 19United States, South Africa, Ghana, United Kingdom, Zambia
-
Centers for Disease Control and Prevention, ChinaCenters for Disease Control and Prevention; Zhejiang Provincial Center for... and other collaboratorsCompletedJapanese Encephalitis | Measles | RubellaChina
-
The 458 Hospital of Chinese PLAGuangzhou Baidi Biotechnology Co., Ltd; Guangzhou Pharmaceucal Company LimitedUnknownChronic Hepatitis B Patients With HBeAg-positiveChina